Daniel Long Sells 3,333 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $34.36, for a total transaction of $114,521.88. Following the completion of the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at approximately $3,312,716.32. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Septerna Price Performance

Shares of SEPN stock opened at $34.00 on Friday. The company’s fifty day simple moving average is $30.06 and its two-hundred day simple moving average is $27.65. Septerna, Inc. has a 1 year low of $10.62 and a 1 year high of $37.99. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -41.97 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. Equities research analysts anticipate that Septerna, Inc. will post -1.59 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Stifel Nicolaus assumed coverage on Septerna in a research note on Friday, May 1st. They issued a “buy” rating and a $43.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $60.00 price target on shares of Septerna in a report on Tuesday, March 10th. JPMorgan Chase & Co. raised their price objective on shares of Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Finally, Guggenheim reduced their price objective on shares of Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Septerna currently has an average rating of “Moderate Buy” and a consensus price target of $45.89.

Institutional Investors Weigh In On Septerna

Large investors have recently added to or reduced their stakes in the business. Woodline Partners LP grew its position in Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after buying an additional 282,585 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Septerna by 16.6% in the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after acquiring an additional 3,323 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after acquiring an additional 78,316 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after purchasing an additional 1,315 shares in the last quarter. Finally, CW Advisors LLC purchased a new position in shares of Septerna during the second quarter worth about $133,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.